Red Blood Cell & Iron Disorders

Red Blood Cell & Iron Disorders

A collection of features and news articles published in ASH Clinical News related to red blood cell and iron disorders.

WIB_icon

BIOIRON Society Recommends New Classification of Hemochromatosis

During a meeting of clinicians and basic scientists in Heidelberg, Germany, a working group of the International Society for the Study of Iron in...

Anemia, Inflammation Associated With Worse Outcomes in Patients With Coronary Artery Disease

Anemia is strongly associated with immune activation in patients with coronary artery disease (CAD), and a combination of both anemia and increased markers for...
WIB_icon

Characterizing Long-Term Outcomes of Eltrombopag in Patients With Severe Aplastic Anemia

In an analysis of a phase II trial published in Blood, researchers found that the addition of eltrombopag to standard immunosuppression led to similar...
Sickle cell anemia

Voxelotor Granted Priority Review for Children With Sickle Cell Disease

The U.S. Food and Drug Administration (FDA) has accepted Global Blood Therapeutics’ (GBT’s) supplemental New Drug Application (sNDA) seeking accelerated approval for voxelotor for...

Crizanlizumab Approved for Sickle Cell Disease in the U.K.

Crizanlizumab will become the first new therapy in 20 years to be made available through the U.K.’s National Health Service (NHS) for the treatment...

Conserving Red Blood Cell Units in the Treatment of Patients With SCD During Blood...

The ongoing COVID-19 pandemic has led to severe blood shortages within the health care delivery system, disproportionately affecting the supply of red blood cells...

FDA Committee Votes Against Approval of Roxadustat for Anemia of Chronic Kidney Disease

The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has decided not to recommend the approval of roxadustat for the treatment of patients with...
WIB_icon

Danicopan Improves Hemoglobin, Reduces Transfusion Requirements in Eculizumab-Treated Patients With PNH

First-in-class oral factor D inhibitor danicopan improved hemoglobin (Hb) and reduced transfusion requirements in transfusion-dependent patients with paroxysmal nocturnal hemoglobinuria (PNH) who had previously...
On location

PDE9 Inhibitor Shows Promise as Monotherapy and With Hydroxyurea in Sickle Cell Disease

Data from two new studies indicated that daily dosing of the oral phosphodiesterase type 9 (PDE9) inhibitor IMR-687, at doses up to 200 mg,...

Study Finds Specialized Infusion Centers Offer Better Care for Patients with SCD

A new study published in the Annals of Internal Medicine found that patients with sickle cell disease (SCD) experiencing acute pain crises received better...
Advertisement

Current Issue

November 2021 Bonus ASH Annual Meeting Preview Edition

This issue offers a behind-the-scenes look at this year's annual meeting, and more.

Block title